key: cord-0919671-7zfe8594
authors: Amin, Deepak; McKitish, Kristin; Shah, Prakesh S
title: Association of Mortality and Recent M. Pneumoniae Infection in COVID‐19 Patients
date: 2020-08-27
journal: J Med Virol
DOI: 10.1002/jmv.26467
sha: 8b08c47f563b8a048b756cd87ef03135a5ba92e0
doc_id: 919671
cord_uid: 7zfe8594

OBJECTIVE: To compare characteristics and outcomes of patients who had COVID‐19 with M. Pneumoniae Immunoglobulin M (IgM) antibodies to those without M Pneumoniae antibodies. METHODS: We retrospectively reviewed cases admitted over a 4‐week period between March 17, 2020 and April 14, 2020 to the Hoboken University Medical Center, New Jersey, USA. We compared the outcomes COVID‐19 patients who were positive for M. Pneumoniae IgM with those who were negative for M. Pneumoniae IgM. Primary outcome was mortality. Adjusted odds ratio was calculated after controlling for baseline differences. RESULTS: Of 139 patients admitted with COVID‐19, 79 were positive for M. Pneumoniae IgM. The mortality among those who were M. Pneumoniae IgM positive was significantly higher (adjusted odds ratio 2.28, 95% confidence interval 1.03 to 5.03) compared to those who were M. Pneumoniae IgM negative. CONCLUSION: Patients with coinfection ( COVID‐19 & mycoplasma) has higher mortality compared to patients with just COVID‐19 disease. This article is protected by copyright. All rights reserved.

Mycoplasma. Pneumoniae affects 3 to 10% of patients with respiratory tract diseases described a case series of 5700 patients with COVID-19 admitted to intensive care units in

Pneumoniae: A potentially Fever >38 0 C, n (%)

Mycoplasma IgM negative group was still in hospital at time of chart review. Abbreviations: BMI, body mass index